Neurim Pahrmaceuticals and BIOCODEX undertake a license agreement that enlists the fact that BIOCODEX will possess the exclusive marketing rights to market Neurim’s Rx paediatric product in Finland.
Neurim’s PedPRM implies to treat sleep disorders in autism spectrum disorders (ASD) and neurogenetic disease afflicted children. Neurim Pharmaceuticals claims it to be the first allegedly sleep drug sanctioned for children.
Nava Zisapel, CEO of Neurim Pharmaceuticals claimed ” We are pleased to expand our partnership with Biocodex and confident in Biocodex Oy ability to bring this much needed treatment to Finland. Our team is working diligently to make our new treatment accessible for the children and their families in additional markets.”
Tessa Ahosalmi, General Manager of Biocodex Oy said “We are much delighted to build our partnership with Neurim – their development and clinical expertise have led them to be on the front line on understanding and the treatment of insomnia.”
Image Source : Neurim Pharmaceuticals